Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.

Alessandra Di Bacco,Allison Berger,Neeraj Gupta,Feng Gao,Stephen J. Blakemore,Mark G. Qian,Susan Chen,Bradley Stringer,Yu Yang,Ray Liu,Stephen Tirrell,Doug Bowman,David C. Smith,Daniel C. Sullivan,Jeffrey R. Infante,John S. Kauh,Lillian L. Siu,Gordana Vlahovic,John A. Thompson,Thea Kalebic

Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.

2012

3077 Background: MLN9708 is a potent investigational proteasome inhibitor, which upon intravenous (IV) administration immediately hydrolyzes to the active form MLN2238. MLN9708 is currently being e...

Keywords:

Pathology
Distribution (pharmacology)
Proteasome inhibitor
Cancer research
Medicine
Oncology
Internal medicine
target engagement
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations